Novo wins UK approval as race to launch weight-loss pill intensifies
Decision brief
Answer first · skim in under a minute
Novo Nordisk won UK approval for its oral Wegovy weight-loss pill, making the UK the first European market to allow access. The decision strengthens Novo’s lead in the oral GLP-1 race as Eli Lilly advances orforglipron.
Key questions this brief answers
- When did the UK approve oral Wegovy?
- Is the oral Wegovy tablet available on the NHS?
- What is the oral Wegovy dose schedule?
Race launch weight-loss pill heats intensified on 11 June 2026 when the MHRA approved Novo Nordisk’s oral semaglutide (Wegovy) tablet for weight management. The UK becomes the first European market to authorize the GLP-1 tablet, while NHS access still awaits NICE evaluation.
Contents11 sections
Key Takeaways
- MHRA approved the semaglutide (Wegovy) tablet for weight loss and weight management on 11 June 2026.
- Eligible adults include BMI ≥30, or BMI 27–30 with at least one weight-related comorbidity, alongside diet and activity.
- Tablet dosing starts at 1.5 mg once daily, then 4 mg, 9 mg, and 25 mg, with at least one month at each level.
- The tablet is UK-approved but not currently available via the NHS pending NICE and related processes.
What did the MHRA approve on 11 June 2026?
The Medicines and Healthcare products Regulatory Agency approved the UK’s first GLP-1 receptor agonist tablet for weight loss and weight management. Authorisation for the new indication for the semaglutide (Wegovy) tablet was granted to Novo Nordisk on 11 June 2026.
Details are in the MHRA press release on GOV.UK. Julian Beach of the MHRA said the product met standards of safety, quality, and effectiveness and remains prescription-only.
Who can be prescribed the oral Wegovy tablet?
Alongside a reduced-calorie diet and increased physical activity, the tablet may be prescribed to adults with obesity (BMI of 30 or above) or who are overweight with BMI between 27 and 30 and at least one weight-related comorbidity.
Patients already on private 2.4 mg once-weekly semaglutide injection can transition straight to 25 mg tablets once daily, according to MHRA. Administration rules matter: take the tablet whole on an empty stomach after fasting at least 8 hours, with a sip of water, then wait at least 30 minutes before food or drink.
How does dosing escalate for the tablet?
The starting dose is 1.5 mg once daily, increasing to 4 mg, 9 mg, and 25 mg, with a minimum of one month at each dose level. Common side effects include gastrointestinal disorders such as nausea, diarrhoea, constipation, and vomiting.
Semaglutide mimics GLP-1 to reduce hunger and support lower calorie intake. MHRA will keep safety under review via the Yellow Card scheme. Related EU obesity coverage is at EU obesity category pages.
Why does the race launch weight-loss pill heat matter commercially?
A Reuters industry factbox on 11 June 2026 framed the oral GLP-1 race as multiple top pharma companies push first-to-market pills after injectables scaled globally. Novo’s UK first-mover status creates a European reference for labeling, supply, and private-channel launch sequencing.
See Reuters’ 11 June 2026 factbox. NHS availability remains closed until NICE and commissioning steps conclude, so private-channel dynamics may dominate early UK volumes.
What should competitors and payers watch next?
Watch NICE timelines, manufacturing scale for the 25 mg tablet, and how injectable-to-oral switches are coded in private clinics. Rival oral candidates will be judged against MHRA’s dosing and fasting instructions as a practical adherence barrier.
Compare portfolio strategy with Novo Nordisk company coverage and other MHRA regulatory moves.
What clinical and pharmacovigilance follow-up is required?
MHRA notes Summaries of Product Characteristics and Patient Information Leaflets publish on the MHRA Products website within seven days of approval. Prescribers should counsel on fasting windows that affect absorption.
Report suspected adverse reactions through Yellow Card. Long-term cardiovascular labeling questions for oral formulations should be tracked against injectable Wegovy evidence rather than assumed identical.
How will private UK channels behave before NHS listing?
Private clinics already familiar with weekly injectable semaglutide may switch eligible patients to the 25 mg tablet where clinically appropriate. Fasting rules and thirty-minute post-dose restrictions will shape adherence support scripts.
Supply allocation between injectable and oral SKUs will influence list prices and discounting. Wholesalers should track MHRA product listings within seven days of approval when SmPC and PIL documents appear on the MHRA Products website.
What European regulatory dominoes could follow the UK decision?
Other European regulators will watch UK pharmacovigilance and real-world adherence before mirroring oral GLP-1 labels. Manufacturers racing oral candidates will cite the UK dosing ladder when designing bridging packages.
Payers outside the UK will still demand local health-technology assessments. The MHRA decision is a regulatory first, not an automatic reimbursement template for EU member states or for NICE itself.
Frequently Asked Questions
When did the UK approve oral Wegovy?
The MHRA approved the semaglutide (Wegovy) tablet for weight loss and weight management on 11 June 2026.
Is the oral Wegovy tablet available on the NHS?
Not currently. MHRA said NHS use will follow established processes, including NICE evaluation.
What is the oral Wegovy dose schedule?
Dosing starts at 1.5 mg once daily and increases to 4 mg, 9 mg, and 25 mg, with at least one month at each dose level.
